[1]杨文彦.雷珠单抗玻璃体腔注射联合激光治疗对糖尿病视网膜病变患者视力水平的影响[J].医学信息,2023,36(11):110-113.[doi:10.3969/j.issn.1006-1959.2023.11.021]
　YANG Wen-yan.Effect of Intravitreal Injection of Ranibizumab Combined with Laser Therapy on Visual Acuity in Patients with Diabetic Retinopathy[J].Journal of Medical Information,2023,36(11):110-113.[doi:10.3969/j.issn.1006-1959.2023.11.021]
点击复制

雷珠单抗玻璃体腔注射联合激光治疗对糖尿病视网膜病变患者视力水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年11期
页码:
110-113
栏目:
论著
出版日期:
2023-06-01

文章信息/Info

Title:
Effect of Intravitreal Injection of Ranibizumab Combined with Laser Therapy on Visual Acuity in Patients with Diabetic Retinopathy
文章编号:
1006-1959（2023）11-0110-04
作者:
杨文彦
（启东市人民医院眼科，江苏 启东 226200）
Author(s):
YANG Wen-yan
(Ophthalmology Department of Qidong People’s Hospital,Qidong 226200,Jiangsu,China)
关键词:
糖尿病视网膜病变; 雷珠单抗玻璃体腔注射; 激光治疗; 最佳矫正视力; 黄斑中心凹厚度
Keywords:
Diabetic retinopathy; Intravitreal injection of ranibizumab; Laser therapy; Best corrected visual acuity; Foveal thickness
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2023.11.021
文献标志码:
A
摘要:
目的 探究雷珠单抗玻璃体腔注射（IVR）联合激光治疗对糖尿病视网膜病变（DR）患者视力水平的影响。方法 以2021年1月-12月启东市人民医院眼科收治的100例DR患者为研究对象，采用随机数字表法分为对照组（50例）和观察组（50例）。对照组行激光治疗，观察组采用IVR联合激光治疗，比较两组临床疗效、激光治疗参数（光斑数量、激光能量、能量密度）、黄斑中心凹厚度（CMT）、最佳矫正视力（BCVA）、并发症。结果 观察组治疗有效率高于对照组（P＜0.05）；观察组光斑数量、激光能量、能量密度均小于对照组（P＜0.05）；治疗后3个月，两组CMT小于治疗前，BCVA大于治疗前，且观察组CMT小于对照组，BCVA大于对照组（P＜0.05）；观察组并发症发生率小于对照组（P＜0.05）。结论 IVR联合激光治疗DR疗效肯定，可削减黄斑中心凹视网膜厚度，改善患者视力，同时减少激光治疗所需的能量参数，降低其并发症风险。
Abstract:
Objective To investigate the effect of intravitreal injection of ranibizumab (IVR) combined with laser therapy on visual acuity in patients with diabetic retinopathy (DR).Methods A total of 100 patients with DR admitted to the Department of Ophthalmology, Qidong People’s Hospital from January to December 2021 were selected as the research objects and divided into control group (50 patients) and observation group (50 patients) by random number table method. The control group was treated with laser, and the observation group was treated with IVR combined with laser. The clinical efficacy, laser treatment parameters (spot number, laser energy, energy density), central macular thickness (CMT), best corrected visual acuity (BCVA) and complications were compared between the two groups.Results The effective rate of treatment in the observation group was higher than that in the control group (P<0.05). The number of spots, laser energy and energy density in the observation group were smaller than those in the control group (P<0.05). At 3 months after treatment, CMT in the two groups was less than that before treatment, BCVA was greater than that before treatment, and CMT in the observation group was less than that in the control group, BCVA was greater than that in the control group (P<0.05). The incidence of complications in the observation group was lower than that in the control group (P<0.05).Conclusion IVR combined with laser is effective in the treatment of DR, which can reduce the macular foveal retinal thickness, improve the visual acuity of patients, reduce the energy parameters required for laser treatment, and reduce the risk of complications.

参考文献/References:

[1]王嫄,杜兆江,王甜甜,等.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞继发黄斑水肿疗效及安全性观察[J].贵州医药,2022,46(6):947-948.[2]徐冰,史喜红,白雪.眼底激光联合雷珠单抗对糖尿病视网膜病变及静脉阻塞引起黄斑水肿患者视力情况的影响研究[J].检验医学与临床,2022,19(7):962-964.[3]颜坚,蔡玉莲,邓江涛,等.玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗视网膜静脉阻塞继发黄斑水肿的临床疗效[J].中南医学科学杂志,2021,49(6):717-720.[4]林翎,卢毓敏,马胜生.雷珠单抗联合眼底激光治疗糖尿病视网膜病变的疗效[J].实用医学杂志,2021,37(20):2660-2664.[5]Lang GE,Stahl A,Voegeler J,et al.Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study[J].Acta Ophthalmologica,2022,100(2):e578-e587.[6]佘雪飞.雷珠单抗球内注射联合眼底激光治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中国药物与临床,2020,20(5):741-743.[7]张娴,SAME.Mansour,施恩.玻璃体腔注射雷珠单抗对老年PDR合并AMD患者的疗效研究[J].重庆医学,2020,49(2):188-191,196.[8]中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.[9]Roy S,Kern TS,Song B,et al.Mechanistic Insights into Pathological Changes in the Diabetic Retina:Implications for Targeting Diabetic Retinopathy[J].The American Journal of Pathology,2017,187(1):9-19.[10]陈伽俐,李炜,李林.雷珠单抗联合577 nm激光光凝治疗重度非增生型糖尿病视网膜病变伴黄斑水肿的效果观察[J].河北医科大学学报,2019,40(7):834-837.[11]钟志伟,邵东平.玻璃体腔注射雷珠单抗联合全视网膜光凝及单纯全视网膜光凝治疗高危增殖性糖尿病视网膜病变的对比研究[J].海南医学,2019,30(11):1401-1403.[12]岳建中,夏智渝,张安民,等.IVR联合激光光凝治疗对视网膜静脉阻塞继发黄斑水肿患者VEGF、CRT、BCVA、眼压的影响[J].临床误诊误治,2019,32(4):38-43.[13]Murtaza S,Saim KM,Ahsan M,et al.Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy[J].Pakistan Journal of Medical Sciences,2017,33(1):142-145.[14]李晓东,王艳青,王李理,等.玻璃体腔注射雷珠单抗治疗糖尿病视网膜病变的临床疗效观察与应用价值分析[J].山西医药杂志,2021,50(4):593-595.[15]孟凡毅,任艳竹,张婉婷.雷珠单抗联合激光治疗糖尿病视网膜病变的疗效[J].国际眼科杂志,2018,18(4):638-641.[16]徐志伟,伍海建,金玲艳,等.单次玻璃体腔注射雷珠单抗联合激光治疗视网膜分支静脉阻塞继发黄斑水肿[J].中华眼视光学与视觉科学杂志,2018,20(3):168-173.[17]宫俊芳,肖华基,周玉婷,等.激光联合雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿的疗效分析[J].中国激光医学杂志,2017,26(5):262-265.[18]王志玉,史爱云.雷珠单抗联合全视网膜激光光凝治疗重度非增生型糖尿病视网膜病变的疗效观察[J].眼科新进展,2017,37(8):776-779,784.[19]陆妍,戴丽丽,张景晖,等.雷珠单抗联合激光光凝治疗PDR及对房水中PAI、t-PA、VEGF水平的影响[J].国际眼科杂志,2020,20(1):45-48.[20]张永红,张晓湄,付鹏.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变患者手术后视力的影响[J].河北医学,2017,23(7):1105-1108.[21]陈圣文,吴子东,李刚.雷珠单抗玻璃体腔注射联合激光与单纯激光治疗糖尿病视网膜病变在视力恢复中的效果比较[J].临床和实验医学杂志,2017,16(18):1800-1802.[22]贾俊,万鹏飞.雷珠单抗辅助治疗增生型糖尿病视网膜病变的疗效和血清Apelin水平的观察[J].中国激光医学杂志,2019,28(5):266-271.

相似文献/References:

[1]郭 明,郑继伟,马丽平.25(OH)D3与糖尿病视网膜病变的关系研究[J].医学信息,2018,31(08):99.[doi:10.3969/j.issn.1006-1959.2018.08.031]
　GUO Ming,ZHENG Ji-wei,MA Li-ping.Study on the Relationship between 25(OH)D3 and Diabetic Retinopathy[J].Journal of Medical Information,2018,31(11):99.[doi:10.3969/j.issn.1006-1959.2018.08.031]
[2]闫宇梅.血清胱抑素C及同型半胱氨酸与2型糖尿病 视网膜病变的相关性分析[J].医学信息,2018,31(17):89.[doi:10.3969/j.issn.1006-1959.2018.17.027]
　YAN Yu-mei.Correlation between Serum Cystatin C and Homocysteine and Type 2 Diabetic Retinopathy[J].Journal of Medical Information,2018,31(11):89.[doi:10.3969/j.issn.1006-1959.2018.17.027]
[3]罗妮娜,金昌德,陈文莉.中西医结合护理在老年糖尿病视网膜病变低视力患者中应用及效果观察[J].医学信息,2018,31(19):165.[doi:10.3969/j.issn.1006-1959.2018.19.052]
　LUO Ni-na,JIN Chang-de,CHEN Wen-li.Application and Effect of Integrated Traditional Chinese and Western Medicine Nursing in Elderly Patients with Diabetic Retinopathy with Low Visual[J].Journal of Medical Information,2018,31(11):165.[doi:10.3969/j.issn.1006-1959.2018.19.052]
[4]宋晨音.他汀类药物在糖尿病治疗中的研究[J].医学信息,2022,35(17):166.[doi:10.3969/j.issn.1006-1959.2022.17.045]
　SONG Chen-yin.Study of Statins in the Treatment of Diabetes Mellitus[J].Journal of Medical Information,2022,35(11):166.[doi:10.3969/j.issn.1006-1959.2022.17.045]
[5]苟青青,李 鸿.糖尿病相关眼部改变及并发症的研究[J].医学信息,2022,35(18):153.[doi:10.3969/j.issn.1006-1959.2022.18.043]
　GOU Qing-qing,LI Hong.Study on Diabetes-related Ocular Changes and Complications[J].Journal of Medical Information,2022,35(11):153.[doi:10.3969/j.issn.1006-1959.2022.18.043]
[6]马 斌,王彩星,王金虹.基于文献计量学的我国2型糖尿病护理研究现状及热点分析[J].医学信息,2021,34(22):12.[doi:10.3969/j.issn.1006-1959.2021.22.004]
　MA Bin,WANG Cai-xing,WANG Jin-hong.Analysis of Current Status and Hot Spots in Nursing Research of Type 2 Diabetes Mellitus in China Based on Bibliometrics[J].Journal of Medical Information,2021,34(11):12.[doi:10.3969/j.issn.1006-1959.2021.22.004]
[7]潘 浩.依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TAOC及TNF-α水平的影响[J].医学信息,2020,33(05):100.[doi:10.3969/j.issn.1006-1959.2020.05.030]
　PAN Hao.Effects of Adjuvant Epalrestat on SOD,TAOC and TNF-α Levels in Patients with Diabetic Retinopathy[J].Journal of Medical Information,2020,33(11):100.[doi:10.3969/j.issn.1006-1959.2020.05.030]
[8]孙天慧,谭晓霞,连晓芬,等.2型糖尿病合并视网膜病变的影响因素分析[J].医学信息,2020,33(21):94.[doi:10.3969/j.issn.1006-1959.2020.21.027]
　SUN Tian-hui,TAN Xiao-xia,LIAN Xiao-fen,et al.Analysis of Influencing Factors of Type 2 Diabetes with Retinopathy[J].Journal of Medical Information,2020,33(11):94.[doi:10.3969/j.issn.1006-1959.2020.21.027]
[9]李 娟,冯双双,康京京,等.尿β2微球蛋白水平与2型糖尿病患者视网膜病变和肾脏病变的相关性[J].医学信息,2020,33(19):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
　LI Juan,FENG Shuang-shuang,KANG Jing-jing,et al.Correlation Between Urine β2 Microglobulin Level and Retinopathy and Nephropathy in Type 2 Diabetic Patients[J].Journal of Medical Information,2020,33(11):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
[10]彭 越,高 宇,王云飞,等.VEGF在糖尿病视网膜病变发病机制中的作用[J].医学信息,2021,34(05):36.[doi:10.3969/j.issn.1006-1959.2021.05.011]
　PENG Yue,GAO Yu,WANG Yun-fei,et al.The Role of VEGF in the Pathogenesis of Diabetic Retinopathy[J].Journal of Medical Information,2021,34(11):36.[doi:10.3969/j.issn.1006-1959.2021.05.011]

更新日期/Last Update: 1900-01-01